CLORICROMEN HYDROCHLORIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C20H26ClNO5.ClH
Molecular Weight	432.338
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.CCOC(=O)COC1=C(Cl)C2=C(C=C1)C(C)=C(CCN(CC)CC)C(=O)O2

InChI

InChIKey=CCCZJRFQJNGCCU-UHFFFAOYSA-N

InChI=1S/C20H26ClNO5.ClH/c1-5-22(6-2)11-10-15-13(4)14-8-9-16(26-12-17(23)25-7-3)18(21)19(14)27-20(15)24;/h8-9H,5-7,10-12H2,1-4H3;1H

HIDE SMILES / InChI

Molecular Formula	C20H26ClNO5
Molecular Weight	395.877
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7867874 | https://www.ncbi.nlm.nih.gov/pubmed/16572308 | https://www.ncbi.nlm.nih.gov/pubmed/17593009

Cloricromen a drug that inhibits platelet aggregation in man and in experimental thrombosis. Experiments on rodents have revealed that cloricromene which reduced tumor necrosis factor production, could be useful in the treatment of periodontitis. In addition, it could be potentially useful in ischemic-retinal diseases where amelioration of blood flow and inflammation is desirable. However, experiments with patients with cerebrovascular occlusive disease didn’t shown any effect of cloricromen on coagulative variables.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
platelet aggregation 76 Target ID: GO:0070527 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7867874 \| https://www.genome.jp/dbget-bin/www_bget?D07139 \| https://www.ncbi.nlm.nih.gov/pubmed/8220889	Inhibitor 8297
NF-kappa B signaling pathway 84 Target ID: map04064 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15322736	Inhibitor 8297

PubMed

Title	Date	PubMed
Cloricromene, a coumarine derivative, reduced the development of periodontitis in rats.	2006 Apr	16572308
Protective effects of a coumarin derivative in diabetic rats.	2009 Aug	19279317

Sample Use Guides

In Vivo Use Guide

Twenty patients with a history of atherothrombotic stroke received cloricromen (100 mg, twice daily) for 30 days in order to evaluate its effects on plasma fibrinogen, antithrombin III, and other variables of the haemostatic system

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:53:19 GMT 2023` Edited by `admin` on `Fri Dec 15 16:53:19 GMT 2023`
Record UNII	931696CA9T
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CLORICROMEN HYDROCHLORIDE

Common Name

English

CLORICROMEN HYDROCHLORIDE [MI]

Common Name

English

PROENDOTEL

Brand Name

English

Cloricromen hydrochloride [WHO-DD]

Common Name

English

CLORICROMEN HCL

Common Name

English

((8-CHLORO-3-(2-(DIETHYLAMINO)ETHYL)-4-METHYL-2-OXO-2H-1-BENZOPYRAN-7-YL)OXY)ACETIC ACID ETHYL ESTER HYDROCHLORIDE

Systematic Name

English

Code System Code Type Description

CAS

74697-28-2